Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System
09. Juli 2024 08:00 ET
|
Curonix LLC
Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System.
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
18. Januar 2024 08:00 ET
|
Curonix LLC
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
Curonix Celebrates 1st Anniversary
01. November 2023 09:00 ET
|
Curonix LLC
POMPANO BEACH, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Today, Curonix LLC, a leading peripheral nerve stimulation company celebrated its first anniversary. In November 2022, Curonix completed the...
Retrospective clinical study highlights the effectiveness of Curonix’s Freedom® PNS System in reducing pain scores and improving patient satisfaction
10. August 2023 08:00 ET
|
Curonix LLC
POMPANO BEACH, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to freeing patients from chronic pain, announced the publication of a retrospective study...
Curonix Provides Reimbursement Update on Neurostimulator Procedure Codes
18. Juli 2023 08:00 ET
|
Curonix LLC
POMPANO BEACH, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- Today, Curonix LLC provided an update on the Medicare Physician Fee Schedule Proposed Rule published by the Centers for Medicare & Medicaid...
Independent clinical study shows Curonix’s Freedom® PNS System significantly reduces pain scores and medication usage
07. Juni 2023 07:00 ET
|
Curonix LLC
POMPANO BEACH, Fla., June 07, 2023 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to freeing patients from chronic pain, announced the publication of 24 months of data from...